Compare Indinavir (Indinavir Sulfate) with Modern HIV Treatment Alternatives
Nov, 18 2025
HIV Treatment Comparison Tool
Compare HIV Treatment Options
Select two treatments to compare key features and understand why modern regimens have replaced Indinavir.
Indinavir sulfate, sold under the brand name Crixivan, was once a game-changer in the fight against HIV. Introduced in the mid-1990s, it was one of the first protease inhibitors that helped turn HIV from a death sentence into a manageable condition. But today, if someone is starting HIV treatment, they won’t be prescribed Indinavir. Why? Because better options exist-ones that are simpler, safer, and more effective.
What Indinavir Actually Did
Indinavir works by blocking HIV protease, an enzyme the virus needs to copy itself. Without it, new virus particles can’t mature and become infectious. When it launched in 1996, combining Indinavir with two nucleoside reverse transcriptase inhibitors (NRTIs) like zidovudine and lamivudine slashed viral loads and boosted CD4 counts in most patients. For the first time, people with HIV were living longer, healthier lives.
But the downsides were serious. Patients had to take Indinavir every eight hours-three times a day-on an empty stomach. No food within an hour before or after. That’s not just inconvenient; it’s impossible to stick to long-term. Side effects included kidney stones (in up to 15% of users), nausea, diarrhea, and abnormal fat redistribution. Many patients stopped taking it because the burden outweighed the benefit.
Why Indinavir Is No Longer Used
By 2010, most guidelines had already stopped recommending Indinavir. The reason? New drugs came along that didn’t require strict fasting, didn’t cause kidney stones, and worked better with fewer pills.
The FDA withdrew the brand-name version, Crixivan, in 2016. Generic versions are still technically available, but no major health authority-WHO, CDC, EACS, or DHHS-recommends it for new patients. Even in resource-limited settings, where cost matters most, newer generics like dolutegravir or tenofovir-based combinations have replaced it.
Indinavir is now a historical footnote in HIV treatment. It helped build the foundation, but it’s not part of the modern toolkit.
Top Modern Alternatives to Indinavir
Today’s first-line HIV regimens are usually single-pill, once-daily combinations. They’re easier, safer, and more effective. Here are the main alternatives that have replaced Indinavir:
- Dolutegravir (DTG): An integrase inhibitor. Taken once daily, with no food restrictions. Less than 1% of patients experience serious side effects. It’s the global standard for first-line treatment.
- Bictegravir (BIC): Also an integrase inhibitor, found in Biktarvy. Combines with tenofovir alafenamide and emtricitabine in one pill. High barrier to resistance, excellent safety profile.
- Elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (Genvoya): Another single-pill option. Less kidney toxicity than older tenofovir formulations.
- Raltegravir (RAL): An earlier integrase inhibitor, still used in some cases. Requires twice-daily dosing, so it’s less preferred than dolutegravir or bictegravir.
- Darunavir (DRV) with ritonavir or cobicistat: A newer protease inhibitor. Unlike Indinavir, it’s taken once daily with food and has a much lower risk of kidney stones.
These drugs don’t just work better-they’re designed for real life. No fasting. No complex schedules. Fewer side effects. Higher adherence rates. And better long-term outcomes.
Indinavir vs. Modern Drugs: Key Differences
Here’s how Indinavir stacks up against today’s top alternatives:
| Feature | Indinavir Sulfate | Dolutegravir | Bictegravir | Darunavir |
|---|---|---|---|---|
| Dosing frequency | Three times daily | Once daily | Once daily | Once daily |
| Food requirements | Empty stomach only | Any time, with or without food | Any time, with or without food | With food |
| Common side effects | Kidney stones, nausea, fat loss | Headache, insomnia (rare) | Headache, diarrhea (mild) | Diarrhea, rash |
| Kidney toxicity risk | High (15% develop stones) | Very low | Very low | Low |
| Barrier to resistance | Low to moderate | High | High | Very high |
| Current guideline recommendation | Not recommended | First-line | First-line | First-line (in specific cases) |
The gap isn’t just about effectiveness-it’s about quality of life. People on modern regimens don’t have to plan their day around pill schedules. They don’t fear kidney stones. They don’t feel punished for eating a snack.
When Might Someone Still Take Indinavir?
There are almost no cases where Indinavir is the right choice today. But in extremely rare situations, it might be used:
- If a patient has severe allergies or resistance to every other drug class (extremely uncommon with modern resistance testing).
- As part of a research protocol studying older drugs in multidrug-resistant HIV.
- In countries with no access to newer medications-though even here, WHO recommends dolutegravir-based regimens as the minimum standard.
Even then, it’s a last resort. No clinician would start someone on Indinavir today unless there was no other option-and even that scenario is vanishingly rare.
What Happens If You’re Still on Indinavir?
If you’re still taking Indinavir-perhaps because you started treatment decades ago and never switched-talk to your provider. Staying on it isn’t dangerous if your viral load is undetectable and you’re not having side effects. But you’re missing out on better outcomes.
Switching to a modern regimen can:
- Reduce your risk of kidney disease by up to 70%
- Improve your ability to stick to your meds
- Lower your chance of developing drug resistance
- Improve your energy, mood, and overall well-being
Most switches are safe and simple. Your doctor will test your virus for resistance, pick a compatible new drug, and monitor you for a few weeks. Many people report feeling better within months.
Why Modern Drugs Are the Clear Winner
Modern HIV drugs aren’t just improvements-they’re a revolution. They’re not just about killing the virus. They’re about letting people live.
Indinavir was a breakthrough for its time. But medicine doesn’t stand still. Today’s treatments are so good that people on them have near-normal life expectancies. They can have children without passing on HIV. They can travel, work, and live without fear.
There’s no reason to hold onto a drug from the 1990s when you could be on a single pill, taken once a day, with no food restrictions and almost no side effects.
Frequently Asked Questions
Is Indinavir still available today?
Yes, generic Indinavir sulfate is still manufactured and available in some countries, but it’s no longer marketed or recommended by any major health organization. Most pharmacies won’t stock it because it’s rarely prescribed.
Can Indinavir be used with modern HIV drugs?
It’s not advised. Indinavir interacts with many modern drugs, especially those metabolized by the liver enzyme CYP3A4. Combining it with integrase inhibitors like dolutegravir or bictegravir can lead to unpredictable drug levels, increasing the risk of side effects or treatment failure.
Why was Indinavir so hard to take?
Indinavir had very low bioavailability unless taken on an empty stomach. Even a small snack could cut its absorption in half. That meant patients had to time doses around meals, which disrupted sleep, work, and social life. This made adherence extremely difficult-leading to drug resistance in many cases.
Do any newer protease inhibitors still require fasting?
No. Modern protease inhibitors like darunavir are formulated to be taken with food, which improves absorption and reduces side effects. Even boosted versions (with cobicistat or ritonavir) don’t require strict fasting schedules.
What should I do if I’m currently taking Indinavir?
Schedule an appointment with your HIV provider. They’ll check your viral load, kidney function, and drug resistance profile. If everything’s stable, switching to a modern regimen is safe and strongly recommended. Most people transition smoothly within 4-6 weeks.
Next Steps
If you’re on Indinavir or know someone who is, the next step is simple: talk to your doctor. Bring this information with you. Ask about switching to a once-daily, single-pill regimen. Ask about kidney health. Ask about long-term risks.
If you’re newly diagnosed, don’t even consider Indinavir. Ask for dolutegravir, bictegravir, or darunavir-based regimens. These are the gold standard. They’re proven, safe, and designed for real life.
HIV treatment has come a long way. You deserve the best. There’s no reason to settle for a drug that’s been left behind by science.
Kenneth Meyer
November 19, 2025 AT 18:32It’s wild to think that a drug requiring you to starve yourself three times a day was ever considered a miracle. We used to celebrate small victories because we had no choice. Now we have options that don’t make you feel like a prisoner to your own body. The real breakthrough wasn’t just the science-it was the shift from survival to living.
Indinavir didn’t just treat HIV-it punished those who had it. And yet, people still took it. Not because they wanted to, but because they were told it was their only shot. That’s the tragedy of medical progress: sometimes the first step is the cruelest one.
Today’s regimens aren’t just better-they’re humane. That’s not a technical detail. That’s a moral one.
I wonder how many people died not from HIV, but from the burden of its treatment.
Medicine should never ask you to choose between health and dignity.
Will Phillips
November 20, 2025 AT 18:12They say indinavir is obsolete but who really controls the narrative here huhbig pharma they pushed these new drugs hard and now they own your life with monthly bills and mandatory lab testsyou think you’re free but you’re just on a different leashthe side effects are hidden and the resistance is comingthey don’t want you cured they want you subscribedask yourself why are all the old drugs pulled but the new ones cost 10xit’s not science it’s profitthey replaced indinavir with a subscription model
Arun Mohan
November 21, 2025 AT 05:20Let’s be honest-Indinavir was a relic from a time when medicine still believed suffering was a prerequisite for efficacy. Modern HIV treatment isn’t just superior-it’s elegant. Dolutegravir? A single pill. No fasting. No kidney stones. Just… life.
It’s like comparing a horse-drawn carriage to a Tesla. The fact that anyone still clings to Indinavir isn’t nostalgia-it’s negligence.
And don’t get me started on how the West hoards these drugs while the Global South gets scraps. Dolutegravir is cheaper than coffee in some places now. Yet people still die because of supply chains and bureaucracy, not science.
We didn’t evolve because we were smart. We evolved because we refused to accept that suffering was inevitable.
Indinavir was the past. The future is already here. You just have to stop being lazy enough to use it.
Tyrone Luton
November 22, 2025 AT 23:08It’s funny how we romanticize the past. Indinavir was a step-yes-but it was a step made of glass. People took it because they were told it was the best, not because it was good.
Modern drugs aren’t just more effective-they’re more respectful. They assume you’re human. That you have a job. A family. A life that doesn’t revolve around pill schedules.
And yet, we still treat medical progress like a luxury. As if anyone should have to choose between dignity and survival.
There’s a quiet arrogance in saying ‘we used to be grateful for this.’ No. We were desperate. There’s a difference.
What’s changed isn’t just the science. It’s our willingness to demand better. And that’s the real revolution.
darnell hunter
November 23, 2025 AT 14:21Indinavir was discontinued because it was pharmacologically inferior and logistically unsustainable. Modern antiretrovirals exhibit superior pharmacokinetic profiles, reduced nephrotoxicity, and enhanced adherence metrics. The clinical evidence is unequivocal. The World Health Organization, Centers for Disease Control and Prevention, and European AIDS Clinical Society all concur: Indinavir is obsolete. Any continued use constitutes a deviation from standard of care and potentially endangers patient outcomes. This is not opinion. It is guideline-based medicine.
Hannah Machiorlete
November 23, 2025 AT 15:01i just read this whole thing and i’m crying not because i’m sad but because i’m so madhow many people died because they couldn’t afford to switch or their doctor didn’t care enough to tell themthey’re still on indinavir and no one checked in for yearsit’s not just about pills it’s about being seenyou don’t just need a better drug you need someone who remembers you’re alive
Bette Rivas
November 25, 2025 AT 00:41It’s important to recognize that the shift from Indinavir to modern regimens isn’t just about pharmacology-it’s about public health infrastructure. The success of dolutegravir and bictegravir isn’t accidental. It’s the result of decades of research, investment in generic manufacturing, and global advocacy for equitable access.
Indinavir’s failure wasn’t just its side effects-it was its incompatibility with real-world adherence. People don’t fail treatment because they’re lazy. They fail because the regimen is designed for an idealized life that doesn’t exist for most.
Modern drugs work because they were designed with human behavior in mind: once-daily dosing, no food restrictions, minimal drug interactions, and high genetic barriers to resistance.
And when we talk about kidney stones, we’re not just talking about discomfort-we’re talking about hospitalizations, lost wages, and chronic pain. That’s not a trade-off. That’s a failure of care.
The fact that we can now offer a single-pill regimen with near-zero side effects means we’ve finally stopped treating HIV as a punishment and started treating it as a chronic condition worthy of dignity.
What’s remarkable isn’t that we replaced Indinavir-it’s that we dared to imagine something better and then made it real.
prasad gali
November 25, 2025 AT 10:20Indinavir’s pharmacokinetic profile was suboptimal-low bioavailability, CYP3A4-mediated metabolism, narrow therapeutic window. Modern INSTIs like DTG and BIC offer higher potency, lower off-target effects, and superior resistance profiles. The PIs like darunavir, when boosted, have improved bioavailability and reduced pill burden. The clinical data is overwhelming: adherence rates increased by 40–60% post-transition. Mortality declined. Viral suppression improved. The paradigm shift isn’t anecdotal-it’s statistically significant and globally validated. Any continued use of Indinavir outside of clinical trials is a deviation from evidence-based practice.
Paige Basford
November 26, 2025 AT 14:11My uncle’s been on Indinavir since 2001. He’s 72, has never missed a dose, and his viral load is undetectable. He says he’s not changing because ‘if it ain’t broke.’
But I showed him the stats-how switching cut his kidney risk by 70%, how he could drop from 6 pills to 1, how he could eat pizza without timing his meds like a NASA launch.
He cried. Not because he was scared. Because he realized no one ever asked him if he wanted to live easier.
It’s not just about the science. It’s about asking, ‘Do you want to keep surviving… or do you want to start living?’
He’s switching next month. I’m so proud of him.
And yeah-I cried too.
Ankita Sinha
November 27, 2025 AT 14:52I’m from India. When I got diagnosed in 2018, I was told dolutegravir wasn’t available in my city. I got a generic combo that was still better than anything from the 90s.
But I met a man at the clinic who’d been on Indinavir since 1999. He said he didn’t know there were better options. His doctor retired. No one told him.
He had kidney stones. He couldn’t afford the flight to Delhi to switch. He didn’t even know he could.
That’s the real tragedy-not that Indinavir was bad, but that people still have to live with it because no one told them they deserve more.
Science moved forward. But the system didn’t catch up.
So I started a small group. We translate info. We help people get tested. We make sure no one has to choose between dignity and a pill schedule.
You don’t need a miracle. You just need someone to say: ‘You’re worth more than this.’